Related Experiment Video
Updated: Aug 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Short- and long-term safety of glaucoma drugs
1New England Eye Center, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Box 450, Boston, MA 02111, USA. jss2002@attbi.com
Abstract:
Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of molecules including beta-adrenergic blockers, cholinergic agents, alpha-adrenergic agonists, carbonic anhydrase inhibitors and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Ophthalmic Drug Delivery Systems

